

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* \* \* \* \* Welcome to STN International \* \* \* \* \* \* \* \* \*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 JAN 02 STN pricing information for 2008 now available  
NEWS 3 JAN 16 CAS patent coverage enhanced to include exemplified prophetic substances  
NEWS 4 JAN 28 USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats  
NEWS 5 JAN 28 MARPAT searching enhanced  
NEWS 6 JAN 28 USGENE now provides USPTO sequence data within 3 days of publication  
NEWS 7 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment  
NEWS 8 JAN 28 MEDLINE and LMEDLINE reloaded with enhancements  
NEWS 9 FEB 08 STN Express, Version 8.3, now available  
NEWS 10 FEB 20 PCI now available as a replacement to DPCI  
NEWS 11 FEB 25 IFIREF reloaded with enhancements  
NEWS 12 FEB 25 IMSPRODUCT reloaded with enhancements  
NEWS 13 FEB 29 WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification  
NEWS 14 MAR 31 IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats  
NEWS 15 MAR 31 CAS REGISTRY enhanced with additional experimental spectra  
NEWS 16 MAR 31 CA/CAplus and CASREACT patent number format for U.S. applications updated  
NEWS 17 MAR 31 LPCI now available as a replacement to LDPCI  
NEWS 18 MAR 31 EMBASE, EMBAL, and LEMBASE reloaded with enhancements  
NEWS 19 APR 04 STN AnaVist, Version 1, to be discontinued  
NEWS 20 APR 15 WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats  
NEWS 21 APR 28 EMBASE Controlled Term thesaurus enhanced  
NEWS 22 APR 28 IMSRESEARCH reloaded with enhancements

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,  
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 08:20:25 ON 17 MAY 2008

=> file medline, biosis, wpids, uspatful, dgene, embase, biotechds  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST 0.42 0.42

FILE 'MEDLINE' ENTERED AT 08:21:20 ON 17 MAY 2008

FILE 'BIOSIS' ENTERED AT 08:21:20 ON 17 MAY 2008  
Copyright (c) 2008 The Thomson Corporation

FILE 'WPIDS' ENTERED AT 08:21:20 ON 17 MAY 2008  
COPYRIGHT (C) 2008 THOMSON REUTERS

FILE 'USPATFULL' ENTERED AT 08:21:20 ON 17 MAY 2008  
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 08:21:20 ON 17 MAY 2008  
COPYRIGHT (C) 2008 THE THOMSON CORPORATION

FILE 'EMBASE' ENTERED AT 08:21:20 ON 17 MAY 2008  
Copyright (c) 2008 Elsevier B.V. All rights reserved.

FILE 'BIOTECHDS' ENTERED AT 08:21:20 ON 17 MAY 2008  
COPYRIGHT (C) 2008 THOMSON REUTERS

=> s protein dimierization  
L1 0 PROTEIN DIMIERIZATION

=> s (method) and (protein dimerization)  
5 FILES SEARCHED...

L3 266 L2 AND (FUSION)

L4 101 L3 AND (METHOTREXATE AND LIGAND)

L5 0 L4 AND (METHOTREXATE-LEXA)

## L6 27 L4 AND COVALENT BOND

L7 16 L6 AND (DIHYDROFOLATE)

✓ a 1, ex abs 1515 see

## ANSWER 1 OF 10 - SPARQL ON SINGULARITY

### Binding constructs and methods

AB The invention relates to novel binding domain constructs and methods for use thereof.

AB The invention relates to novel binding domain immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a wild-type IgG, IGA or IgE hinge-acting region, i.e., IgE CH2, region polypeptide

or a mutant IgGI hinge region polypeptide having either zero, one or two cysteine residues, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as polypeptides that are compromised in their ability to form disulfide-linked multimers. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including cell surface forms of the fusion proteins and immunotherapeutic applications of the fusion proteins and of polynucleotides encoding such fusion proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2007:271553 USPATFULL  
TITLE: Binding constructs and methods for use thereof  
INVENTOR(S): Ledbetter, Jeffrey A., Shoreline, WA, UNITED STATES  
Hayden-Ledbetter, Martha Susan, Shoreline, WA, UNITED STATES  
Thompson, Peter Armstrong, Bellevue, WA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007237779	A1	20071011
APPLICATION INFO.:	US 2003-566409	A1	20031224 (10)
	WO 2003-US41600		20031224
			20060824 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-10627556	20030726
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MARSHALL, GERSTEIN & BORUN LLP, 233 S. WACKER DRIVE, SUITE 6300, SEARS TOWER, CHICAGO, IL, 60606, US	
NUMBER OF CLAIMS:	413	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	88 Drawing Page(s)	
LINE COUNT:	20337	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 2 OF 16 USPATFULL on STN  
TI Immunoglobulin chimeric monomer-dimer hybrids  
AB The invention relates to a chimeric monomer-dimer hybrid protein wherein said protein comprises a first and a second polypeptide chain, said first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and said second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2007:197585 USPATFULL  
TITLE: Immunoglobulin chimeric monomer-dimer hybrids  
INVENTOR(S): Peters, Robert T., West Roxbury, MA, UNITED STATES  
Mezo, Adam R., Waltham, MA, UNITED STATES  
Rivera, Daniel S., Providence, RI, UNITED STATES  
Bitonti, Alan J., Acton, MA, UNITED STATES  
Low, Susan C., Pepperell, MA, UNITED STATES  
PATENT ASSIGNEE(S): Syntonix Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
--	--------	------	------

PATENT INFORMATION: US 2007172928 A1 20070726  
APPLICATION INFO.: US 2006-588431 A1 20061027 (11)  
RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-841250, filed on 6 May  
2004, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-469600P	20030506 (60)
	US 2003-487964P	20030717 (60)
	US 2004-539207P	20040126 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 901 NEW YORK AVENUE, NW, WASHINGTON, DC, 20001-4413, US	
NUMBER OF CLAIMS:	2	
EXEMPLARY CLAIM:	1-197	
NUMBER OF DRAWINGS:	27 Drawing Page(s)	
LINE COUNT:	5222	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L7 ANSWER 3 OF 16 USPATFULL on STN  
TI Cell proliferation-related polypeptides and uses therefor  
AB Disclosed are proteins, and nucleic acids encoding such proteins,  
involved in or associated with cell proliferation, senescence,  
differentiation, development, and stress response in plants. Also  
disclosed are uses for such proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
ACCESSION NUMBER: 2006:296744 USPATFULL  
TITLE: Cell proliferation-related polypeptides and uses  
therefor  
INVENTOR(S): Cooper, Bret, 9339 Creekview Drive, Laurel, MD, UNITED  
STATES 20708

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006253917	A1	20061109
APPLICATION INFO.:	US 2003-533232	A1	20031223 (10)
	WO 2003-US41200		20031223
			20051122 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-436565P	20021226 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JENKINS, WILSON, TAYLOR & HUNT, P. A., 3100 TOWER BLVD, SUITE 1200, DURHAM, NC, 27707, US	
NUMBER OF CLAIMS:	58	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	16 Drawing Page(s)	
LINE COUNT:	12776	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L7 ANSWER 4 OF 16 USPATFULL on STN  
TI Stress-related polypeptides and uses therefor  
AB Disclosed are proteins, and nucleic acids encoding such proteins,  
involved in or associated with the stress response (both biotic and  
abiotic stress) in plants. Also disclosed are uses for such proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2006:275417 USPATFULL  
TITLE: Stress-related polypeptides and uses therefor  
INVENTOR(S): Cooper, Bret, Laurel, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006235215	A1	20061019
APPLICATION INFO.:	US 2003-533176	A1	20031223 (10)
	WO 2003-US41098		20031223
			20060412 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-436564P	20021226 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JENKINS, WILSON, TAYLOR & HUNT, P. A., 3100 TOWER BLVD, SUITE 1200, DURHAM, NC, 27707, US	
NUMBER OF CLAIMS:	46	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	8854	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 5 OF 16 USPATFULL on STN

TI Immunoglobulin chimeric monomer-dimer hybrids  
AB The invention relates to a chimeric monomer-dimer hybrid protein wherein said protein comprises a first and a second polypeptide chain, said first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and said second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:298530 USPATFULL  
TITLE: Immunoglobulin chimeric monomer-dimer hybrids  
INVENTOR(S): Peters, Robert T., West Roxbury, MA, UNITED STATES  
Mezo, Adam R., Waltham, MA, UNITED STATES  
Rivera, Daniel S., Providence, RI, UNITED STATES  
Bitonti, Alan J., Acton, MA, UNITED STATES  
Low, Susan C., Pepperell, MA, UNITED STATES  
Stattel, James, Leominster, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005260194	A1	20051124
	US 7348004	B2	20080325
APPLICATION INFO.:	US 2005-29003	A1	20050105 (11)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2004-841250, filed on 6 May 2004, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-469600P	20030506 (60)
	US 2003-487964P	20030717 (60)
	US 2004-539207P	20040126 (60)
DOCUMENT TYPE:	Utility	

FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP,  
901 NEW YORK AVENUE, NW, WASHINGTON, DC, 20001-4413, US  
NUMBER OF CLAIMS: 131  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 27 Drawing Page(s)  
LINE COUNT: 5395  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 6 OF 16 USPATFULL on STN

TI Bacterial small-molecule three-hybrid system  
AB A transgenic bacterial cell comprising (a) a dimeric small molecule which comprises a first moiety known to bind a first receptor domain covalently linked to a second moiety known to bind a second receptor domain; (b) nucleotide sequences which upon transcription encode i) a first fusion protein comprising the first receptor domain, and ii) a second fusion protein comprising the second receptor domain; and (c) a reporter gene wherein expression of the reporter gene is conditioned on the proximity of the first fusion protein to the second fusion protein. The cell is also adapted for use in a method for identifying a molecule that binds to a known target in a bacterial cell from a pool of candidate molecules, and a method for identifying an unknown target receptor to which a molecule is capable of binding in a bacterial cell. Also described are compounds and kits for carrying out the methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:254908 USPATFULL  
TITLE: Bacterial small-molecule three-hybrid system  
INVENTOR(S): Althoff, Eric A, 526 West 122nd Street, #5C, New York, NY, UNITED STATES 10027  
PATENT ASSIGNEE(S): Cornish, Virginia W, New York, NY, UNITED STATES  
Trustees Of Columbia University In The City Of New York, New York, NY, UNITED STATES, 10027 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005221402	A1	20051006
APPLICATION INFO.:	US 2003-512497	A1	20030424 (10)
	WO 2003-US12612		20030424
			20050523 PCT 371 date
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-132039, filed on 24 Apr 2002, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	COOPER & DUNHAM, LLP, 1185 AVENUE OF THE AMERICAS, NEW YORK, NY, 10036, US		
NUMBER OF CLAIMS:	37		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Page(s)		
LINE COUNT:	1531		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L7 ANSWER 7 OF 16 USPATFULL on STN

TI Binding constructs and methods for use thereof  
AB The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a wild-type IgG1, IGA or IgE hinge-acting region, i.e., IgE CH2, region polypeptide or a mutant IgG1 hinge region polypeptide having either zero, one or two

cysteine residues, and immunoglobulin CH<sub>2</sub> and CH<sub>3</sub> domains, and that are capable of ADCC and/or CDC while occurring predominantly as polypeptides that are compromised in their ability to form disulfide-linked multimers. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including cell surface forms of the fusion proteins and immunotherapeutic applications of the fusion proteins and of polynucleotides encoding such fusion proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:157841 USPATFULL  
TITLE: Binding constructs and methods for use thereof  
INVENTOR(S): Ledbetter, Jeffrey A., Shoreline, WA, UNITED STATES  
                  Hayden-Ledbetter, Martha, Shoreline, WA, UNITED STATES  
                  Thompson, Peter A., Bellevue, WA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005136049	A1	20050623
APPLICATION INFO.:	US 2003-627556	A1	20030726 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-53530, filed on 17 Jan 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-367358P	20010117 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BUCHANAN INGERSOLL, P.C., ONE OXFORD CENTRE, 301 GRANT STREET, 20TH FLOOR, PITTSBURGH, PA, 15219, US	
NUMBER OF CLAIMS:	110	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	75 Drawing Page(s)	
LINE COUNT:	19086	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 8 OF 16 USPATFULL on STN

TI Adzymes and uses thereof  
AB Disclosed is a family of novel protein constructs, useful as drugs and for other purposes, termed "adzymes," comprising an address moiety and a catalytic domain. In some types of disclosed adzymes, the address binds with a binding site on or in functional proximity to a targeted biomolecule, e.g., an extracellular targeted biomolecule, and is disposed adjacent the catalytic domain so that its affinity serves to confer a new specificity to the catalytic domain by increasing the effective local concentration of the target in the vicinity of the catalytic domain. The present invention also provides pharmaceutical compositions comprising these adzymes, methods of making adzymes, DNA's encoding adzymes or parts thereof, and methods of using adzymes, such as for treating human subjects suffering from a disease, such as a disease associated with a soluble or membrane bound molecule, e.g., an allergic or inflammatory disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:87403 USPATFULL  
TITLE: Adzymes and uses thereof  
INVENTOR(S): Afeyan, Noubar B., Lexington, MA, UNITED STATES  
                  Lee, Frank D., Chestnut Hill, MA, UNITED STATES  
                  Wong, Gordon G., Brookline, MA, UNITED STATES  
                  Das Gupta, Ruchira, Auburndale, MA, UNITED STATES  
                  Baynes, Brian, Somerville, MA, UNITED STATES

PATENT ASSIGNEE(S): COMPOUND THERAPEUTICS, INC., Waltham, MA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005074865	A1	20050407
APPLICATION INFO.:	US 2004-792498	A1	20040302 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-650592, filed on 27 Aug 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-406517P	20020827 (60)
	US 2002-423754P	20021105 (60)
	US 2002-430001P	20021127 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: FISH & NEAVE IP GROUP, ROPES & GRAY LLP, ONE INTERNATIONAL PLACE, BOSTON, MA, 02110-2624

NUMBER OF CLAIMS: 45

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 25 Drawing Page(s)

LINE COUNT: 9195

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 9 OF 16 USPATFULL on STN

TI Immunoglobulin chimeric monomer-dimer hybrids

AB The invention relates to a chimeric monomer-dimer hybrid protein wherein said protein comprises a first and a second polypeptide chain, said first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and said second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:37495 USPATFULL

TITLE: Immunoglobulin chimeric monomer-dimer hybrids

INVENTOR(S): Peters, Robert T., West Roxbury, MA, UNITED STATES  
Mezo, Adam R., Waltham, MA, UNITED STATES  
Rivera, Daniel S., Providence, RI, UNITED STATES  
Bitonti, Alan J., Acton, MA, UNITED STATES  
Stattel, James, Leominster, MA, UNITED STATES  
Low, Susan C., Pepperell, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005032174	A1	20050210
APPLICATION INFO.:	US 2004-841250	A1	20040506 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-487964P	20030717 (60)
	US 2004-539207P	20040126 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Finnegan, Henderson, Farabow,, Garrett & Dunner, L.L.P., 1300 I Street, N.W., Washington, DC, 20005-3315

NUMBER OF CLAIMS: 154

EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 27 Drawing Page(s)  
LINE COUNT: 5512  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 10 OF 16 USPATFULL on STN  
TI Methods for chemically synthesizing immunoglobulin chimeric proteins  
AB The invention provides methods of chemically synthesizing chimeric proteins comprising at least a portion of an immunoglobulin constant region and a biologically active molecule.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
ACCESSION NUMBER: 2005:31671 USPATFULL  
TITLE: Methods for chemically synthesizing immunoglobulin chimeric proteins  
INVENTOR(S): Mezo, Adam R., Waltham, MA, UNITED STATES  
Peters, Robert T., West Roxbury, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005027109	A1	20050203
APPLICATION INFO.:	US 2004-842054	A1	20040506 (10)

  

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-469600P	20030506 (60)
	US 2003-487964P	20030717 (60)
	US 2004-539207P	20040126 (60)

  

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: Finnegan, Henderson, Farabow,, Garrett & Dunner,  
L.L.P., 1300 I Street, N.W., Washington, DC, 20005-3315  
NUMBER OF CLAIMS: 34  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 7 Drawing Page(s)  
LINE COUNT: 3085  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 11 OF 16 USPATFULL on STN  
TI Adzymes and uses thereof  
AB Disclosed is a family of novel protein constructs, useful as drugs and for other purposes, termed "adzymes," comprising an address moiety and a catalytic domain. In some types of disclosed adzymes, the address binds with a binding site on or in functional proximity to a targeted biomolecule, e.g., an extracellular targeted biomolecule, and is disposed adjacent the catalytic domain so that its affinity serves to confer a new specificity to the catalytic domain by increasing the effective local concentration of the target in the vicinity of the catalytic domain. The present invention also provides pharmaceutical compositions comprising these adzymes, methods of making adzymes, DNA's encoding adzymes or parts thereof, and methods of using adzymes, such as for treating human subjects suffering from a disease, such as a disease associated with a soluble or membrane bound molecule, e.g., an allergic or inflammatory disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
ACCESSION NUMBER: 2004:107249 USPATFULL  
TITLE: Adzymes and uses thereof  
INVENTOR(S): Afeyan, Noubar B., Lexington, MA, UNITED STATES  
Lee, Frank D., Chestnut Hill, MA, UNITED STATES  
Wong, Gordon G., Brookline, MA, UNITED STATES

Das Gupta, Ruchira, Auburndale, MA, UNITED STATES  
Baynes, Brian, Somerville, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004081648	A1	20040429
APPLICATION INFO.:	US 2003-650592	A1	20030827 (10)

  

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-406517P	20020827 (60)
	US 2002-423754P	20021105 (60)
	US 2002-430001P	20021127 (60)

  

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: ROPES & GRAY LLP, ONE INTERNATIONAL PLACE, BOSTON, MA, 02110-2624  
NUMBER OF CLAIMS: 156  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 19 Drawing Page(s)  
LINE COUNT: 8325  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 12 OF 16 USPATFULL on STN

TI Adzymes and uses thereof

AB Disclosed is a family of novel protein constructs, useful as drugs and for other purposes, termed "adzymes," comprising an address moiety and a catalytic domain. In some types of disclosed adzymes, the address binds with a binding site on or in functional proximity to a targeted biomolecule, e.g., an extracellular targeted biomolecule, and is disposed adjacent the catalytic domain so that its affinity serves to confer a new specificity to the catalytic domain by increasing the effective local concentration of the target in the vicinity of the catalytic domain. The present invention also provides pharmaceutical compositions comprising these adzymes, methods of making adzymes, DNA's encoding adzymes or parts thereof, and methods of using adzymes, such as for treating human subjects suffering from a disease, such as a disease associated with a soluble or membrane bound molecule, e.g., an allergic or inflammatory disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:107248 USPATFULL  
TITLE: Adzymes and uses thereof  
INVENTOR(S): Afeyan, Noubar B., Lexington, MA, UNITED STATES  
Lee, Frank D., Chestnut Hill, MA, UNITED STATES  
Wong, Gordon G., Brookline, MA, UNITED STATES  
DasGupta, Ruchira, Auburndale, MA, UNITED STATES  
Baynes, Brian, Somerville, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004081647	A1	20040429
APPLICATION INFO.:	US 2003-650591	A1	20030827 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-406517P	20020827 (60)
	US 2002-423754P	20021105 (60)
	US 2002-430001P	20021127 (60)

  

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: ROPES & GRAY LLP, ONE INTERNATIONAL PLACE, BOSTON, MA, 02110-2624  
NUMBER OF CLAIMS: 41  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 19 Drawing Page(s)  
LINE COUNT: 7919  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 13 OF 16 USPATFULL on STN  
TI Bacterial small-molecule three-hybrid system  
AB A transgenic bacterial cell comprising  
  
(a) a dimeric small molecule which comprises a first moiety known to bind a first receptor domain covalently linked to a second moiety known to bind a second receptor domain;  
  
(b) nucleotide sequences which upon transcription encode  
  
i) a first fusion protein comprising the first receptor domain, and  
  
ii) a second fusion protein comprising the second receptor domain; and  
  
(c) a reporter gene wherein expression of the reporter gene is conditioned on the proximity of the first fusion protein to the second fusion protein. The cell is also adapted for use in a method for identifying a molecule that binds to a known target in a bacterial cell from a pool of candidate molecules, and a method for identifying an unknown target receptor to which a molecule is capable of binding in a bacterial cell. Also described are compounds and kits for carrying out the methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
ACCESSION NUMBER: 2003:288713 USPATFULL  
TITLE: Bacterial small-molecule three-hybrid system  
INVENTOR(S): Althoff, Eric A., New York, NY, UNITED STATES  
Cornish, Virginia W., New York, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003203471	A1	20031030
	US 7083918	B2	20060801
APPLICATION INFO.:	US 2002-132039	A1	20020424 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, NY, 10036		
NUMBER OF CLAIMS:	82		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Page(s)		
LINE COUNT:	1786		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 14 OF 16 USPATFULL on STN  
TI In vivo protein screen based on enzyme-assisted chemically induced dimerization ("CID")  
AB A method for identifying which protein from a pool of candidate proteins catalyzes in a cell a bond forming reaction between a first substrate and a second substrate, comprising:

- (a) providing a dimeric small molecule which comprises a known moiety that binds a known receptor domain covalently linked with a moiety that contains the first substrate;
- (b) introducing the dimeric molecule into a cell which comprises
  - i) a first fusion protein comprising the known receptor domain,
  - ii) a second fusion protein comprising the second substrate,
  - iii) a protein from the pool of candidate proteins, and
  - iv) a reporter gene wherein expression of the reporter gene is conditioned on the proximity of the first fusion protein to the second fusion protein;
- (c) permitting the dimeric molecule to bind to the first fusion protein and to enzymatically form a bond with the second fusion protein so as to activate the expression of the reporter gene;
- (d) selecting which cell expresses the reporter gene; and
- (e) identifying the protein that catalyzes the bond formation reaction in the cell between the first substrate and the second substrate. The method is also adapted to identify which substrate from a pool of candidate substrates is selected in a cell by a known enzyme for a bond forming reaction between the substrate and a known amino acid. Also, cells, compounds and kits for carrying out the methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:200800 USPATFULL

TITLE: In vivo protein screen based on enzyme-assisted chemically induced dimerization ("CID")

INVENTOR(S): Kopytek, Stephan, New York, NY, UNITED STATES  
Cornish, Virginia, New York, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003138785	A1	20030724
APPLICATION INFO.:	US 2002-84388	A1	20020225 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-343467P	20011221 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, NY, 10036	
NUMBER OF CLAIMS:	83	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	11 Drawing Page(s)	
LINE COUNT:	1286	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 15 OF 16 USPATFULL on STN

TI Binding and catalysis screen for high throughput determination of protein function using chemical inducers of dimerization

AB A method for screening a cDNA library by identifying the expressed protein target, comprising:

- (a) providing a screening molecule comprising a methotrexate moiety or an analog of methotrexate covalently bonded to a ligand which has a known specificity;
- (b) introducing the screening molecule into a cell which expresses a first fusion protein comprising a binding domain capable of binding methotrexate, a second fusion protein comprising the expressed unknown protein target, and a reporter gene wherein expression of the reporter gene is conditioned on the proximity of the first fusion protein to the second fusion protein;
- (c) permitting the screening molecule to bind to the first fusion protein and to the second fusion protein so as to activate the expression of the reporter gene;
- (d) selecting which cell expresses the reporter gene; and
- (e) identifying the unknown protein target and the corresponding cDNA.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:301193 USPATFULL

TITLE: Binding and catalysis screen for high throughput determination of protein function using chemical inducers of dimerization

INVENTOR(S): Cornish, Virginia W., New York, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002168737	A1	20021114
APPLICATION INFO.:	US 2001-768474	A1	20010124 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	John P. White, Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, NY, 10036		
NUMBER OF CLAIMS:	19		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	25 Drawing Page(s)		
LINE COUNT:	1784		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 16 OF 16 USPATFULL on STN  
 TI Covalent chemical inducers of protein dimerization  
     and their uses in high throughput binding screens  
 AB Described are compounds having the formula:

H1-Y-H2

where H1 is a substrate capable of selectively binding to a first receptor; where H2 is a substrate capable of selectively binding to and selectively forming a covalent bond with a second receptor; and wherein Y is a moiety providing a covalent linkage between H1 and H2, which may be present or absent, and when absent, H1 is covalently linked to H2. Also described are uses of the compounds for in vivo screening of compounds and proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:301142 USPATFULL

TITLE: Covalent chemical inducers of protein dimerization and their uses in high throughput binding screens

INVENTOR(S): Cornish, Virginia W., New York, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002168685	A1	20021114
APPLICATION INFO.:	US 2002-56874	A1	20020124 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-768474, filed on 24 Jan 2001, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	John P. White, Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, NY, 10036		
NUMBER OF CLAIMS:	54		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	24 Drawing Page(s)		
LINE COUNT:	1954		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

=>